5-Amino-1MQ Protocol
Small-molecule NNMT inhibitor studied for fat-metabolism and cellular-energy research.
- Cycle
- 8–12 weeks
Evidence Level: Investigational / Theoretical
Primarily preclinical or very limited human data — mechanism-based reasoning more than a demonstrated clinical effect. Treat as investigational.
Human evidence: Minimal published human trial data.
Animal evidence: Rodent NNMT-inhibition and adiposity studies form the primary evidence base.
Introduction & Mechanism of Action
Small-molecule NNMT inhibitor studied for fat-metabolism and cellular-energy research.
Inhibits nicotinamide N-methyltransferase (NNMT), an enzyme implicated in adipocyte energy storage; oral small molecule rather than an injectable peptide.
Receptors/targets: Not receptor-mediated — enzymatic inhibition of NNMT
Areas of Research Interest
- NNMT-pathway research
- Fat-metabolism studies
Benefits Reported in Research
- Fat-metabolism research
- NNMT-pathway studies
Reported Research Dosing Range
The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.
Reported range: 50–150 mg
Reported frequency: 1× daily, oral
Reported cycle duration: 8–12 weeks
Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.
Side Effects
- Not well quantified in controlled human trials
Contraindications
- Pregnancy
- Not established for use with hepatic impairment
Drug interactions
- Not characterized in controlled human trials
Safety
- Long-term safety data essentially absent given sparse human trials
Human clinical evidence is sparse relative to preclinical interest; not an approved therapeutic.
Expected Results & Comparison
Distinct mechanism from every GLP-1/GIP/glucagon agonist in the catalog — it is an oral enzyme inhibitor, not an injectable receptor agonist, so it is not a substitute research pathway for incretin-class compounds.